Ashkenazi ovarian cancer individuals with BRCA mutations live longer than those with normal gene Israeli investigators have discovered that Ashkenazi Jewish women with ovarian cancer who’ve mutations in the BRCA1 or BRCA2 genes lived significantly longer than Ashkenazi Jewish ovarian cancer patients without these mutations. After up to nine years of follow-up, BRCA1/2 mutation carriers were 28 % less inclined to die from the condition, even though ladies with the BRCA mutations are significantly more more likely to develop ovarian and breasts cancers symptoms of anxiety disorder . The study is being published January 1 in the Journal of Clinical Oncology . Mutations in these genes, which are more common among Ashkenazi Jewish females than in the general population, increase the risk of breast and ovarian cancers.
Ascend Biopharmaceuticals reviews favourable outcomes from TG1042 Phase 2 research for CBCL treatment Ascend Biopharmaceuticals, a Melbourne-based immunotherapy firm, has today announced the publication of a report utilising TG1042 for the treating Cutaneous B-Cell Lymphoma , in the journal PLOS 1. Ascend Biopharmaceuticals entered into an exclusive world-wide license agreement with Transgene in July of 2013 to develop TG1042 as an immunotherapeutic injection for multiple cancers including Cutaneous B-Cell Lymphoma, CBCL . Ascend programs to sponsor and commence clinical research with TG1042 in Basal Cell Carcinoma later in 2014. Related StoriesLiposomal sizing and the Coulter theory: an interview with Professor Melvin E.